Advice
Medicine withdrawn
On 30 April, 2020, the licence for ingenol mebutate (Picato), for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults, was withdrawn.
Medicine details
- Medicine name:
- ingenol mebutate gel (Picato)
- SMC ID:
- 851/13
- Indication:
Cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.
- Pharmaceutical company
- LEO Pharmaceuticals
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 11 March 2013
Additional notes
On 30 April 2020, the European Medicines Agency published a statement advising Picato is no longer authorised in the EU as the marketing authorisation was withdrawn in February 2020 at the request of LEO Laboratories Ltd.
In line with SMC process, the SMC advice has been removed from the website.